Arsalan Talib Hashmi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Arsalan Talib Hashmi has a total of 48 co-authors. Here are the top co-authors by number of shared publications:
- Osama Mukhtar
Department of Internal Medicine, Interfaith Medical Center, Brooklyn, NY, USA
3 shared publications A Aslam
Department of Internal Medicine, Maimonides Medical Center , 4802 10th Avenue, Brooklyn, NY 11219, USA
2 shared publicationsC Henriquez-Felipe
Department of Cardiology, Maimonides Medical Center From the , 4802 10th Avenue, Brooklyn, NY 11219, USA
2 shared publicationsD Sharma
Department of Internal Medicine, Maimonides Medical Center , 4802 10th Avenue, Brooklyn, NY 11219, USA
2 shared publications- Geurys Rojas-Marte
Department of Cardiology, Deborah Heart and Lung Center, Browns Mills, NJ, United States of America
2 shared publications J Le
Department of Cardiology, Maimonides Medical Center From the , 4802 10th Avenue, Brooklyn, NY 11219, USA
2 shared publications
Latest Publications
- 1 January 2022
- Published by American Medical Association (AMA) in JAMA Cardiology
- Vol. 7 (1) , 108-109
A Teenager With Palpitations
A teenage patient presents with intermittent palpitations and chest pain associated with shortness of breath. What would you do next?
- 1 January 2022
- Published by American Medical Association (AMA) in JAMA Cardiology
- Vol. 7 (1) , 108-109
A Teenager With Palpitations
A teenage patient presents with intermittent palpitations and chest pain associated with shortness of breath. What would you do next?
- Open Access
- 14 January 2021
- Published by Oxford University Press (OUP) in QJM: An International Journal of Medicine
- Vol. 116 (8) , 733
Corrigendum to: Outcomes in patients with severe COVID-19 disease treated with tocilizumab: a case–controlled study
QJM: An International Journal of Medicine 2020; 00:546–550.
- 14 January 2021
- Published by Oxford University Press (OUP) in QJM: An International Journal of Medicine
- Vol. 116 (8) , 733
Open AccessCorrigendum to: Outcomes in patients with severe COVID-19 disease treated with tocilizumab: a case–controlled study
QJM: An International Journal of Medicine 2020; 00:546–550.
- Open Access
- 2 September 2020
- Published by Greater Baltimore Medical Center in Journal of Community Hospital Internal Medicine Perspectives
- Vol. 10 (5) , 436-442
In-hospital outcomes of angiography versus intravascular ultrasound-guided percutaneous coronary intervention in ST-elevation myocardial infarction patients
We compared the in-hospital complications, outcomes, cost, and length of stay (LOS) between angiography-guided percutaneous coronary intervention (PCI) and intravascular ultrasound (IVUS)-guided PC...
- 2 September 2020
- Published by Greater Baltimore Medical Center in Journal of Community Hospital Internal Medicine Perspectives
- Vol. 10 (5) , 436-442
Open AccessIn-hospital outcomes of angiography versus intravascular ultrasound-guided percutaneous coronary intervention in ST-elevation myocardial infarction patients
We compared the in-hospital complications, outcomes, cost, and length of stay (LOS) between angiography-guided percutaneous coronary intervention (PCI) and intravascular ultrasound (IVUS)-guided PC...
- Open Access
- 19 June 2020
- Published by Oxford University Press (OUP) in QJM: An International Journal of Medicine
- Vol. 113 (8) , 546-550
Outcomes in patients with severe COVID-19 disease treated with tocilizumab: a case–controlled study
COVID-19 is an ongoing threat to society. Patients who develop the most severe forms of the disease have high mortality. The interleukin-6 inhibitor tocilizumab has the potential to improve outcomes in these patients by preventing the development of cytokine release storm. To evaluate the outcomes of patients with severe COVID-19 disease treated with the interleukin-6 inhibitor tocilizumab. We conducted a retrospective, case–control, single-center study in patients with severe to critical COVID-19 disease treated with tocilizumab. Disease severity was defined based on the amount of oxygen supplementation required. The primary endpoint was the overall mortality. Secondary endpoints were mortality in non-intubated patients and mortality in intubated patients. A total of 193 patients were included in the study. Ninety-six patients received tocilizumab, while 97 served as the control group. The mean age was 60 years. Patients over 65 years represented 43% of the population. More patients in the tocilizumab group reported fever, cough and shortness of breath (83%, 80% and 96% vs. 73%, 69% and 71%, respectively). There was a non-statistically significant lower mortality in the treatment group (52% vs. 62.1%, P = 0.09). When excluding intubated patients, there was statistically significant lower mortality in patients treated with tocilizumab (6% vs. 27%, P = 0.024). Bacteremia was more common in the control group (24% vs. 13%, P = 0.43), while fungemia was similar for both (3% vs. 4%, P = 0.72). Our study showed a non-statistically significant lower mortality in patients with severe to critical COVID-19 disease who received tocilizumab. When intubated patients were excluded, the use of tocilizumab was associated with lower mortality.
- 19 June 2020
- Published by Oxford University Press (OUP) in QJM: An International Journal of Medicine
- Vol. 113 (8) , 546-550
Open AccessOutcomes in patients with severe COVID-19 disease treated with tocilizumab: a case–controlled study
COVID-19 is an ongoing threat to society. Patients who develop the most severe forms of the disease have high mortality. The interleukin-6 inhibitor tocilizumab has the potential to improve outcomes in these patients by preventing the development of cytokine release storm. To evaluate the outcomes of patients with severe COVID-19 disease treated with the interleukin-6 inhibitor tocilizumab. We conducted a retrospective, case–control, single-center study in patients with severe to critical COVID-19 disease treated with tocilizumab. Disease severity was defined based on the amount of oxygen supplementation required. The primary endpoint was the overall mortality. Secondary endpoints were mortality in non-intubated patients and mortality in intubated patients. A total of 193 patients were included in the study. Ninety-six patients received tocilizumab, while 97 served as the control group. The mean age was 60 years. Patients over 65 years represented 43% of the population. More patients in the tocilizumab group reported fever, cough and shortness of breath (83%, 80% and 96% vs. 73%, 69% and 71%, respectively). There was a non-statistically significant lower mortality in the treatment group (52% vs. 62.1%, P = 0.09). When excluding intubated patients, there was statistically significant lower mortality in patients treated with tocilizumab (6% vs. 27%, P = 0.024). Bacteremia was more common in the control group (24% vs. 13%, P = 0.43), while fungemia was similar for both (3% vs. 4%, P = 0.72). Our study showed a non-statistically significant lower mortality in patients with severe to critical COVID-19 disease who received tocilizumab. When intubated patients were excluded, the use of tocilizumab was associated with lower mortality.
- Open Access
- 1 January 2020
- Published by SAGE Publications in Journal of Investigative Medicine High Impact Case Reports
- Vol. 8
A Rare Case of Partial Aortic Mechanical Valve Thrombosis With Intact Mitral Mechanical Valve Presenting With ST-Elevation Myocardial Infarction Patients
The incidence of mechanical valve thrombosis (MVT) is around 0.4 per 100 patient-years. Mitral valve thrombosis has a higher incidence than aortic valve thrombosis with a nearly 5-fold increase. Various factors contribute to MVT. The most common cause of valve thrombosis is poor adherence/disruption of anticoagulation therapy. Low cardiac output is known to increase the risk of prosthetic valve thrombosis. Other factors such as diabetes, hypertension, and other patient comorbidities might also play a role. Decreased flow promotes hypercoagulability. Lower pressure in the left atrium (and higher velocities in the left ventricle) can partially contribute to the higher incidence of mitral MVT versus aortic MVT. The presenting symptoms usually depend on the severity of the valve thrombosis; nonobstructive valve thrombosis patients have progressive dyspnea, signs of heart failure, and systemic embolization with strokes being the most common complication. In this article, we present a case of a middle-aged woman with a history of mitral and aortic mechanical prosthesis who presented with an ST-segment elevation myocardial infarction and pulmonary edema due to mechanical aortic valve prosthesis thrombosis. She had an isolated mechanical aortic valve prosthesis thrombosis with intact mitral valve, which, to the best of our knowledge, has not yet been described. We performed a literature review by searching PubMed and Embase using the keywords “mechanical valve,” “thrombosis,” “aortic,” and “mitral,” our search did not show similar cases.
- 1 January 2020
- Published by SAGE Publications in Journal of Investigative Medicine High Impact Case Reports
- Vol. 8
Open AccessA Rare Case of Partial Aortic Mechanical Valve Thrombosis With Intact Mitral Mechanical Valve Presenting With ST-Elevation Myocardial Infarction Patients
The incidence of mechanical valve thrombosis (MVT) is around 0.4 per 100 patient-years. Mitral valve thrombosis has a higher incidence than aortic valve thrombosis with a nearly 5-fold increase. Various factors contribute to MVT. The most common cause of valve thrombosis is poor adherence/disruption of anticoagulation therapy. Low cardiac output is known to increase the risk of prosthetic valve thrombosis. Other factors such as diabetes, hypertension, and other patient comorbidities might also play a role. Decreased flow promotes hypercoagulability. Lower pressure in the left atrium (and higher velocities in the left ventricle) can partially contribute to the higher incidence of mitral MVT versus aortic MVT. The presenting symptoms usually depend on the severity of the valve thrombosis; nonobstructive valve thrombosis patients have progressive dyspnea, signs of heart failure, and systemic embolization with strokes being the most common complication. In this article, we present a case of a middle-aged woman with a history of mitral and aortic mechanical prosthesis who presented with an ST-segment elevation myocardial infarction and pulmonary edema due to mechanical aortic valve prosthesis thrombosis. She had an isolated mechanical aortic valve prosthesis thrombosis with intact mitral valve, which, to the best of our knowledge, has not yet been described. We performed a literature review by searching PubMed and Embase using the keywords “mechanical valve,” “thrombosis,” “aortic,” and “mitral,” our search did not show similar cases.
- 15 March 2019
- Published by Elsevier in European Urology Supplements
- Vol. 18 (1) , e1271
Genitourinary fistulas: Changing patterns of causation and evolution in management
- 15 March 2019
- Published by Elsevier in European Urology Supplements
- Vol. 18 (1) , e1271
Genitourinary fistulas: Changing patterns of causation and evolution in management